You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 10,272,079

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,272,079

Title:	NHE3-binding compounds and methods for inhibiting phosphate transport
Abstract:	Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
Inventor(s):	Carreras Christopher, Charmot Dominique, Jacobs Jeffrey W, Labonte Eric, Lewis Jason G.
Assignee:	ARDELYX, INC.
Application Number:	US14783983
Patent Claims:	5. The method of claim 1 , further comprising administering an additional biologically active agent.6. The method of claim 5 , wherein the additional biologically active agent is a phosphate binder.7. The method of claim 6 , wherein the phosphate binder is selected from the group consisting of sevelamer claim 6 , sevelamer carbonate claim 6 , sevelamer hydrochloride claim 6 , lanthanum carbonate claim 6 , calcium carbonate claim 6 , calcium acetate claim 6 , magnesium carbonate claim 6 , MCI-196 claim 6 , ferric citrate claim 6 , magnesium iron hydroxycarbonate claim 6 , aluminum hydroxide claim 6 , APS1585 claim 6 , SBR-759 claim 6 , and PA-21.8. The method of claim 6 , wherein the phosphate binder is selected from the group consisting of sevelamer carbonate claim 6 , lanthanum carbonate claim 6 , calcium carbonate claim 6 , calcium acetate claim 6 , calcium acetate/magnesium carbonate claim 6 , ferric citrate claim 6 , magnesium iron hydroxycarbonate claim 6 , and aluminum hydroxide.9. The method of claim 6 , wherein the phosphate binder is sevelamer claim 6 , sevelamer carbonate claim 6 , or sevelamer hydrochloride.10. The method of claim 3 , further comprising administering an additional biologically active agent.11. The method of claim 10 , wherein the additional biologically active agent is a phosphate binder.12. The method of claim 11 , wherein the phosphate binder is selected from the group consisting of sevelamer claim 11 , sevelamer carbonate claim 11 , sevelamer hydrochloride claim 11 , lanthanum carbonate claim 11 , calcium carbonate claim 11 , calcium acetate claim 11 , magnesium carbonate claim 11 , MCI-196 claim 11 , ferric citrate claim 11 , magnesium iron hydroxycarbonate claim 11 , aluminum hydroxide claim 11 , APS1585 claim 11 , SBR-759 claim 11 , and PA-21.13. The method of claim 11 , wherein the phosphate binder is selected from the group consisting of sevelamer carbonate claim 11 , lanthanum carbonate claim 11 , calcium carbonate claim 11 , calcium acetate claim 11 , calcium acetate/magnesium carbonate claim 11 , ferric citrate claim 11 , magnesium iron hydroxycarbonate claim 11 , and aluminum hydroxide.14. The method of claim 11 , wherein the phosphate binder is sevelamer claim 11 , sevelamer carbonate claim 11 , or sevelamer hydrochloride.15. The method of claim 3 , wherein the hyperphosphatemia is postprandial hyperphosphatemia.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.